Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616923 · ClinicalTrials.gov registry record · Phase 1
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
A Phase 1 study, sponsored by Albany Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05616923: Completed Phase 1 study, sponsored by Albany Research Institute.
NCT05616923 is a Phase 1 study that has completed, run by Albany Research Institute. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05616923, a Phase 1 study, has completed, sponsored by Albany Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea
Primary Outcome
Weekly assessment of skin irritation, using the Organization for Economic Cooperation and Development test for dermal irritation and corrosion. This test measures cutaneous erythema and edema separately on scales that range from 0 (absence of erythema or edema) to 4 (severe), with higher scores representing worse outcomes.
Interventions
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
What the finished NCT05616923 record still lists
NCT05616923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Trametinib is the first listed.
NCT05616923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05616923 about?
NCT05616923 is a clinical study titled "Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea". This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea
What is the current status of trial NCT05616923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-11-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT05616923?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT05616923?
This trial is sponsored by Albany Research Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05616923's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI